Moreover, patients whose melanomas displayed higher levels of BRAFi-induced autophagy by IHC analysis of LC3 expression experienced fewer partial responses (based on >30% shrinkage of tumor) to vemurafenib and shorter progression-free survival [125], suggesting that autophagy is correlated with the ability of cancer cells to adapt to pathway-targeted inhibition of BRAFV600E signaling. The gene discussed is MAP1LC3A; the disease is melanoma.